Orchestra BioMed Holdings, Inc.
OBIO
$2.64
-$0.14-5.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -26.03% | -15.85% | -32.66% | -23.06% | -31.47% |
| Total Depreciation and Amortization | 16.67% | 7.04% | 1.37% | 4.23% | 2.86% |
| Total Amortization of Deferred Charges | 933.33% | -- | -- | -- | -91.67% |
| Total Other Non-Cash Items | 105.04% | -1.08% | 215.23% | 142.97% | 133.87% |
| Change in Net Operating Assets | -1,075.00% | -204.24% | 401.80% | 58.47% | -223.40% |
| Cash from Operations | -23.36% | -33.24% | 2.71% | 8.81% | -25.50% |
| Capital Expenditure | -3,633.33% | -257.89% | -296.30% | 77.14% | 105.56% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -109.19% | -95.18% | 29.29% | 113.49% | 152.35% |
| Cash from Investing | -111.32% | -95.70% | 28.41% | 113.46% | 152.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -66.67% | 375,775.00% | 98.84% | 63.64% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 230.39% | 375,775.00% | 98.84% | -99.97% | -110.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -129.13% | -29.11% | 117.02% | -564.37% | 114.87% |